Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
StandardStandard
Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. / Gonzalez, J.; Stern, P.; Dutta, S. et al.
Yn: International Journal of Research in Marketing, Cyfrol 25, Rhif 4, 01.12.2008, t. 247–260.
Yn: International Journal of Research in Marketing, Cyfrol 25, Rhif 4, 01.12.2008, t. 247–260.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
HarvardHarvard
Gonzalez, J, Stern, P, Dutta, S & Sismero, C 2008, 'Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules.', International Journal of Research in Marketing, cyfrol. 25, rhif 4, tt. 247–260. https://doi.org/10.1016/j.ijresmar.2008.08.002
APA
Gonzalez, J., Stern, P., Dutta, S., & Sismero, C. (2008). Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. International Journal of Research in Marketing, 25(4), 247–260. https://doi.org/10.1016/j.ijresmar.2008.08.002
CBE
Gonzalez J, Stern P, Dutta S, Sismero C. 2008. Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. International Journal of Research in Marketing. 25(4):247–260. https://doi.org/10.1016/j.ijresmar.2008.08.002
MLA
Gonzalez, J. et al. "Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules.". International Journal of Research in Marketing. 2008, 25(4). 247–260. https://doi.org/10.1016/j.ijresmar.2008.08.002
VancouverVancouver
Gonzalez J, Stern P, Dutta S, Sismero C. Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. International Journal of Research in Marketing. 2008 Rhag 1;25(4):247–260. doi: 10.1016/j.ijresmar.2008.08.002
Author
RIS
TY - JOUR
T1 - Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules.
AU - Gonzalez, J.
AU - Stern, P.
AU - Dutta, S.
AU - Sismero, C.
PY - 2008/12/1
Y1 - 2008/12/1
U2 - 10.1016/j.ijresmar.2008.08.002
DO - 10.1016/j.ijresmar.2008.08.002
M3 - Article
VL - 25
SP - 247
EP - 260
JO - International Journal of Research in Marketing
JF - International Journal of Research in Marketing
SN - 0167-8116
IS - 4
ER -